Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) announced on November 9, 2026 that it has successfully detected fentanyl in human breath samples collected via its Breath Collection Unit and Breath Cartridge technology, with analysis conducted by Omega Laboratories Inc. using liquid chromatography-mass spectrometry. The company describes the achievement as a significant scientific and commercial milestone, extending its platform beyond cannabis testing toward broader multi-drug detection. Investors may be watching this development closely given the growing opioid crisis across North America and the potential workplace safety applications involved.

Key Points

  • Cannabix Technologies Inc. (CSE: BLO) is a Burnaby, B.C.-based developer of breath-based drug and alcohol testing technologies.
  • The company confirmed detection of fentanyl in human breath samples using its BCU and Breath Cartridge platform analysed by Omega Laboratories Inc.
  • Fentanyl appears at trace concentrations in breath — substantially lower than in urine, oral fluid, or blood — making reliable detection technically challenging.
  • Investors may watch for further validation studies and potential commercial applications in workplace safety, transportation, and law enforcement.

Fentanyl Breath Detection Extends the Cannabix BCU Platform Beyond Cannabis

The announcement states that human breath contains fentanyl at trace concentrations substantially lower than those found in traditional biological samples such as urine, oral fluid, or blood. Cannabix reports that its standardised BCU and disposable Breath Cartridges successfully captured and preserved measurable fentanyl quantities from exhaled breath of a drug user, with confirmation provided by Omega Laboratories using LC-MS analysis. The company notes there is very limited historical research demonstrating fentanyl detection in breath, characterising these findings as particularly encouraging for the evolution of its platform.

Broad Multi-Drug Applications Targeted Across Safety and Law Enforcement Sectors

The release states that the multi-drug collection capability is available with the current BCU and Multi-Drug Breath Cartridges, reinforcing what the company describes as its ongoing detection capabilities for opioids, stimulants, and other drugs of abuse. Cannabix identifies potential applications across workplace safety, transportation, substance-use disorder programmes, pain management monitoring, forensic testing, and law enforcement. CEO Rav Mlait stated in the release that the results "further demonstrate the versatility of our technology and its applicability beyond cannabis into broader multi-drug breath testing markets."

Scientific Significance and Commercialisation Challenges Acknowledged

Cannabix acknowledges in the release that collecting and confirming fentanyl in breath is "extremely challenging" given the substance's very low concentrations in exhaled air. The announcement highlights the findings as representing an important step in the evolution of the BCU platform from a THC-focused technology toward a broader multi-panel system. The company did not disclose specific timelines, commercialisation targets, or financing figures in the announcement. The immediate share price impact was not clear from available public information.